Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Royal Bank of Canada
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities research analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a $137.00 price objective on the stock, down from their prior price objective of $138.00. […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities research analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a $137.00 price objective on the stock, down from their prior price objective of $138.00. […]
